NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (instruction) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (instruction)
EP (6) EP1162998B1 (instruction)
JP (4) JP4846906B2 (instruction)
KR (3) KR100798212B1 (instruction)
CN (3) CN1192798C (instruction)
AR (3) AR022963A1 (instruction)
AT (3) ATE346608T1 (instruction)
AU (3) AU750788B2 (instruction)
BE (1) BE1025464I2 (instruction)
BR (4) BR0009154A (instruction)
CA (3) CA2366314C (instruction)
CY (3) CY1107561T1 (instruction)
CZ (3) CZ303653B6 (instruction)
DE (4) DE122009000054I1 (instruction)
DK (2) DK1163000T3 (instruction)
ES (3) ES2275499T3 (instruction)
FR (1) FR10C0008I2 (instruction)
HK (3) HK1043730A1 (instruction)
HU (4) HU229968B1 (instruction)
IL (5) IL145043A0 (instruction)
LU (1) LU91652I2 (instruction)
MX (1) MXPA01009452A (instruction)
MY (2) MY125202A (instruction)
NL (1) NL300415I1 (instruction)
NO (4) NO20014322L (instruction)
NZ (3) NZ513841A (instruction)
PL (3) PL204890B1 (instruction)
PT (2) PT1163000E (instruction)
SI (2) SI1162999T1 (instruction)
TR (3) TR200102739T2 (instruction)
TW (3) TWI286938B (instruction)
WO (3) WO2000056360A2 (instruction)

Families Citing this family (286)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
DE69737413T2 (de) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville Bakterioferritin aus helicobacter pylori
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
PT1163000E (pt) * 1999-03-19 2008-03-20 Glaxosmithkline Biolog Sa Vacina contra antigƩnios de bactƩrias
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
MX357775B (es) 2000-10-27 2018-07-20 J Craig Venter Inst Inc Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
PL226184B1 (pl) 2001-01-23 2017-06-30 Aventis Pasteur Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko
CA2438942A1 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20050106162A1 (en) 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
JP4646516B2 (ja) 2002-02-20 2011-03-09 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ 惐ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ćƒƒć‚Æć‚¹ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ åøē€ć—ćŸćƒćƒŖćƒšćƒ—ćƒćƒ‰å«ęœ‰åˆ†å­ć‚’ęœ‰ć™ć‚‹å¾®ē²’子
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2775098T3 (es) 2002-10-11 2020-07-23 Glaxosmithkline Biologicals Sa Vacunas de polipĆ©ptidos para protecciĆ³n amplia contra linajes meningocĆ³cicos hipervirulentos
EP1551869A2 (en) * 2002-10-15 2005-07-13 Intercell AG Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
DK2395073T3 (en) 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying.
MXPA05005045A (es) 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
PT2279746E (pt) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic ProteĆ­nas de superfĆ­cie de neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
PT2191844E (pt) * 2003-01-30 2014-06-04 Novartis Ag Vacinas injetĆ”veis contra mĆŗltiplos serogrupos meningocĆ³cicos
CN1787839B (zh) 2003-03-07 2011-09-28 ęƒ ę°ęŽ§č‚”å…¬åø ē”ØäŗŽęŠ—åŒ»é™¢å†…ę„ŸęŸ“ēš„免ē–«ēš„多ē³–-葔萄ēƒčŒč”Ø面ē²˜é™„ē“ č½½ä½“蛋ē™½ē¼€åˆē‰©
DK1601689T3 (da) * 2003-03-13 2008-03-25 Glaxosmithkline Biolog Sa OprensningsfremgangsmƄde for bakterielt cytolysin
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas lĆ­quidas para mĆŗltiples serogrupos meningocĆ³cicos
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
RU2432962C2 (ru) 2005-01-27 2011-11-10 Š§ŠøŠ»Š“рŠµŠ½'Š— Š„Š¾ŃŠæŠøтŠ°Š» Š­Š½Š“ Š ŠøсŠµŃ€Ń‡ Š”ŠµŠ½Ń‚ŠµŃ€ Š­Ń‚ ŠžŠŗŠ»ŠµŠ½Š“ Š’Š°ŠŗцŠøŠ½Ń‹ с ŠøсŠæŠ¾Š»ŃŒŠ·Š¾Š²Š°Š½ŠøŠµŠ¼ Š²ŠµŠ·ŠøŠŗуŠ» Š½Š° Š¾ŃŠ½Š¾Š²Šµ gna 1870 шŠøрŠ¾ŠŗŠ¾Š³Š¾ сŠæŠµŠŗтрŠ° Š“ŠµŠ¹ŃŃ‚Š²Šøя Š“Š»Ń ŠæрŠ¾Ń„ŠøŠ»Š°ŠŗтŠøŠŗŠø Š·Š°Š±Š¾Š»ŠµŠ²Š°Š½ŠøŠ¹, Š²Ń‹Š·Ń‹Š²Š°ŠµŠ¼Ń‹Ń… neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
DK1858919T3 (da) 2005-02-18 2012-07-16 Novartis Vaccines & Diagnostic Immunogener fra uropathogen Escherichia coli
EP2351772B1 (en) 2005-02-18 2016-07-13 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
DK1868645T3 (da) * 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensƦtning
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
RU2442825C2 (ru) 2005-04-18 2012-02-20 ŠŠ¾Š²Š°Ń€Ń‚Šøс Š’эŠŗсŠøŠ½ŠµŃ Š­Š½Š“ Š”Š°Š¹ŃŠ³Š½Š¾ŃŃ‚ŠøŠŗс Š˜Š½Šŗ. Š˜Š¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Ń‹Šµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø, сŠæŠ¾ŃŠ¾Š±Ń‹ ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя тŠ°ŠŗŠøх ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠ¹ Šø ŠæŠ»Š°Š·Š¼ŠøŠ“Š°, Š²ŠŗŠ»ŃŽŃ‡ŠµŠ½Š½Š°Ń Š² тŠ°ŠŗŠøŠµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø
AU2006263936B2 (en) 2005-06-27 2010-05-20 Glaxosmithkline Biologicals S.A. Immunogenic composition
ES2443529T3 (es) 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh VacunaciĆ³n mĆŗltiple incluyendo meningococo del serogrupo C
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
JP5215865B2 (ja) 2005-11-22 2013-06-19 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ćƒŽćƒ­ć‚¦ć‚¤ćƒ«ć‚¹ęŠ—åŽŸćŠć‚ˆć³ć‚µćƒć‚¦ć‚¤ćƒ«ć‚¹ęŠ—åŽŸ
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
UA96583C2 (uk) * 2005-12-22 2011-11-25 ŅŠ»Š°ŠŗсŠ¾ŃŠ¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Š· Š”.Š. Š’Š°ŠŗцŠøŠ½Š°, щŠ¾ Š¼Ń–стŠøть ŠŗŠ¾Š½'юŠ³Š°Ń‚Šø ŠŗŠ°ŠæсуŠ»ŃŃ€Š½Š¾Š³Š¾ ŠæŠ¾Š»Ń–сŠ°Ń…Š°Ń€ŠøŠ“у streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MX2008009280A (es) * 2006-01-17 2008-12-12 Arne Forsgren Una nueva proteina de haemophilus influenzae expuesta en la superficie (proteina e; pe).
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
KR101838938B1 (ko) * 2006-03-17 2018-03-15 ė” ź±°ė²„ėؼķŠø ģ˜¤ėøŒ ė” ģœ ė‚˜ģ“ķ‹°ė“œ ģŠ¤ķ…Œģ“ģø  ģ˜¤ėøŒ ģ•„ė©”ė¦¬ģ¹“ ģ—ģ¦ˆ ė ˆķ”„ė¦¬ģ  ķ‹°ė“œ ė°”ģ“ ė” ģ„øķ¬ėŸ¬ķ…Œė¦¬ ģ˜¤ėøŒ ė” ė””ķŒŒķŠøėؼķŠø ģ˜¤ėøŒ ķ—¬ģŠ¤ ģ•¤ė“œ ķœ“ėؼ ģ„œė¹„ģ‹œģ¦ˆ ė³µķ•© ė‹¤ź°€ ė©“ģ—­ģ›ģ„± ģ½˜ģ„¬ź²Œģ“ķŠøģ˜ ģ œģ”° ė°©ė²•
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
DK2004225T3 (da) 2006-03-22 2012-08-06 Novartis Ag Programmer for vaccination med meningocockonjugater
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
BRPI0710210A2 (pt) * 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composiĆ§Ć£o imunogĆŖnica, vacina, mĆ©todos para preparar a vacina, e para prevenir ou tratar infecĆ§Ć£o estafilocĆ³cica, uso da composiĆ§Ć£o imunogĆŖnica, e, processo para conjugar oligassacarƬdeo ou polissacarƬdeo capsular
PE20080129A1 (es) * 2006-03-30 2008-04-08 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
WO2008020335A2 (en) * 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CL2007002909A1 (es) * 2006-10-10 2008-04-18 Wyeth Corp Metodo para reduccion o extraccion de impurezas de proteinas a partir de lisado celular de streptoccocus pneumoniae que comprende calentar dicho lisado, separar a los precipitantes a partir de dicho lisado produciendo un lisado que contiene polisacar
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2008267208B2 (en) * 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2197485B1 (en) 2007-09-12 2015-11-11 GlaxoSmithKline Biologicals SA Gas57 mutant antigens and gas57 antibodies
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag FormulaƧƵes de vacinas meningocĆ³cicas
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
JP2011506334A (ja) 2007-12-07 2011-03-03 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ 免ē–«åæœē­”ć‚’čŖ˜å°Žć™ć‚‹ćŸć‚ć®ēµ„ęˆē‰©
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081274A2 (en) 2007-12-21 2009-07-02 Novartis Ag Mutant forms of streptolysin o
US8226959B2 (en) * 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
US9511131B2 (en) 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
CN102159540B (zh) 2008-07-21 2015-08-12 åøƒčµ–ę±‰å§†å¦‡å„³åŒ»é™¢ äøŽåˆęˆēš„Ī²-1,6č‘”ē³–čƒŗåÆ”ē³–ē›ø关ēš„ę–¹ę³•å’Œē»„合ē‰©
US11065323B2 (en) 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
DK2376108T3 (en) 2008-12-09 2017-04-24 Pfizer Vaccines Llc IgE CH3 peptide vaccine
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
CA2749367A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa AdjuvĆ”lĆ³ H meningococcus faktort kƶtƵ fehĆ©rje
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
SI2510947T1 (sl) 2009-04-14 2016-05-31 Glaxosmithkline Biologicals S.A. Sestavki za imunizacijo proti Staphylococcus aureus
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
CN102481352A (zh) 2009-06-22 2012-05-30 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø é‡‘é»„č‰²č‘”č„ēƒčŒęŠ—原ēš„免ē–«åŽŸę€§ē»„合ē‰©
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
IN2012DN00446A (instruction) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CN104587462B (zh) 2009-09-03 2017-09-26 č¾‰ē‘žē–«č‹—ęœ‰é™č“£ä»»å…¬åø Pcsk9ē–«č‹—
BR112012008338A2 (pt) 2009-09-10 2019-09-24 Novartis Ag combinaĆ§Ć£o de vacinas contra doenƧas do trato respiratĆ³rio.
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydĆ³w otoczkowych staphylococcus aureus typu 5 i typu 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
SG10201506165TA (en) 2009-12-17 2015-09-29 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
EP2515934B1 (en) 2009-12-22 2017-05-17 Celldex Therapeutics, Inc. Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland ProteĆ­nas de uniĆ³n al factor H (fHbp) con propiedades alteradas y mĆ©todos de uso de las mismas
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP6027961B2 (ja) 2010-04-07 2016-11-16 ć‚·ć‚§ćƒ³, 惦ć‚ØSHEN, Yue ē²˜č†œćø化合ē‰©ć‚’é€ć‚‹ćŸć‚ć®åŖ’ä½“ć€ćć‚Œć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ć€ę–¹ę³•ć€åŠć³ć‚·ć‚¹ćƒ†ćƒ 
WO2011146910A1 (en) * 2010-05-20 2011-11-24 Round June L Antigen specific tregs and related compositions, methods and systems
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
HUE048398T2 (hu) * 2010-06-04 2020-07-28 Wyeth Llc VakcinakƩszƭtmƩnyek
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
KR20140026392A (ko) 2011-03-02 2014-03-05 ė…øķŒŒė„“ķ‹°ģŠ¤ ģ•„ź²Œ ģ €ģš©ėŸ‰ģ˜ ķ•­ģ› ė°/ė˜ėŠ” ė³“ģ”°ģ œė„¼ ź°–ėŠ” ģ”°ķ•© ė°±ģ‹ 
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2688590B1 (en) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
KR101711250B1 (ko) 2011-05-06 2017-03-02 ķŽ˜ķŠøė„“ ģ  ė‚˜ė””ģ—ė¹„ģ¹˜ ģ•„ķŒŒė¦° ģ‹œź²”ė¼ ģ†Œė„¤ģ“ ė°•ķ…Œė¦¬ģ•„ģ˜ ģ„øķ¬ģ™ø ė‹¤ė‹¹ė„˜, ģ“ė„¼ ģ œģ”°ķ•˜ėŠ” ė°©ė²•, ģ“ė„¼ ķ•Øģœ ķ•œ ė°±ģ‹  ė° ģ•½ģ œ ģ”°ģ„±ė¬¼
BR112013032410A2 (pt) 2011-06-24 2017-01-17 Epitogenesis Inc composiƧƵes farmacĆŖuticas compreendendo uma combinaĆ§Ć£o de veĆ­culos, vitaminas, taninos e flavonoides de seleĆ§Ć£o como imunomoduladores especĆ­ficos de antĆ­geno
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yƶnelik yƶntemler.
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
JP6170932B2 (ja) 2011-11-07 2017-07-26 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ½“ļ½ļ½’ļ¼ļ¼ļ¼™ļ¼–ęŠ—åŽŸćŠć‚ˆć³ļ½“ļ½ļ½’ļ¼’ļ¼ļ¼’ļ¼‘ęŠ—åŽŸć‚’å«ć‚€ć‚­ćƒ£ćƒŖć‚¢åˆ†å­
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
EP2788022B1 (en) 2011-12-08 2018-10-31 GlaxoSmithKline Biologicals SA Clostridium difficile toxin-based vaccine
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
BR112014016223A8 (pt) 2011-12-29 2017-07-04 Novartis Ag combinaƧƵes adjuvantes de proteĆ­nas de ligaĆ§Ć£o de fator h meningocĆ³cico
US20150273042A1 (en) 2012-02-24 2015-10-01 Novartis Ag Pilus proteins and compositions
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
CN104321078A (zh) 2012-04-26 2015-01-28 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø ęŠ—åŽŸå’ŒęŠ—åŽŸē»„合
KR101728483B1 (ko) 2012-05-04 2017-04-19 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ „ė¦½ģ„  ź“€ė Øėœ ķ•­ģ› ė° ė°±ģ‹  źø°ģž¬ ė©“ģ—­ģ¹˜ė£Œ ģš”ė²•
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
KR102057217B1 (ko) * 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
MX2015002482A (es) 2012-10-03 2016-01-08 Glaxosmithkline Biolog Sa Composicion inmunogenica.
AU2013328548A1 (en) 2012-10-12 2015-05-07 Glaxosmithkline Biologicals Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
BR112015008417A8 (pt) * 2012-10-17 2019-09-10 Glaxosmithkline Biologicals Sa composiĆ§Ć£o imunogĆŖnica, vacina, e, uso de uma composiĆ§Ć£o imunogĆŖnica
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
CA2899787A1 (en) 2013-02-01 2014-08-07 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor agonists
CA2911826C (en) 2013-05-10 2022-08-23 California Institute Of Technology Probiotic prevention and treatment of colon cancer
EP3689375A1 (en) 2013-05-15 2020-08-05 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composiƧƵes de neisseria meningitidis e mƩtodos das mesmas
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2015208821B2 (en) 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HK1223273A1 (zh) 2014-01-21 2017-07-28 č¾‰ē‘žå¤§čÆ厂 č‚ŗē‚Žé“¾ēƒčŒčšč†œå¤šē³–及其ē¼€åˆē‰©
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
KR20160127104A (ko) 2014-02-28 2016-11-02 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė³€ķ˜•ėœ ģˆ˜ė§‰źµ¬ź·  fhbp ķ“ė¦¬ķŽ©ķ‹°ė“œ
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
EP3172224B1 (en) 2014-07-23 2022-06-29 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
FI3244917T3 (fi) 2015-01-15 2023-05-25 Pfizer ImmunogeenisiƤ koostumuksia pneumokokkirokotteissa kƤytettƤvƤksi
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
RU2018104362A (ru) 2015-07-07 2019-08-08 ŠŃ„Ń„ŠøрŠøс ŠŠ³ Š’ŠŠšŠ¦Š˜ŠŠ« Š”Š›ŠÆ Š›Š•Š§Š•ŠŠ˜ŠÆ Š˜ ŠŸŠ ŠžŠ¤Š˜Š›ŠŠšŠ¢Š˜ŠšŠ˜ Š—ŠŠ‘ŠžŠ›Š•Š’ŠŠŠ˜Š™, ŠžŠŸŠžŠ”Š Š•Š”ŠžŠ’ŠŠŠŠ«Š„ IgE
PE20240927A1 (es) 2015-07-21 2024-04-30 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
WO2017033123A1 (en) 2015-08-25 2017-03-02 Babita Agrawal Immunomodulatory compositions and methods of use thereof
CN108290960B (zh) 2015-10-08 2023-06-09 č‰¾ä¼Æ唔大学ē†äŗ‹ä¼š äø™åž‹č‚ē‚Žē—…ęƒe1/e2异äŗŒčšä½“及其ē”Ÿäŗ§ę–¹ę³•
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
JP7099956B2 (ja) 2015-12-04 2022-07-12 惇悤惊 ćƒ•ć‚”ćƒ¼ćƒćƒ¼ ć‚­ćƒ£ćƒ³ć‚µćƒ¼ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒćƒ„ćƒ¼ćƒˆļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ćŒć‚“ć®ę²»ē™‚ć®ćŸć‚ć®ļ½ļ½‰ļ½ƒļ½ļ¼ļ½‚ć‚¢ćƒ«ćƒ•ć‚”ļ¼“ćƒ‰ćƒ”ć‚¤ćƒ³ć«ć‚ˆć‚‹ćƒÆć‚Æćƒćƒ³ęŽ„ēØ®
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
ES2811523T3 (es) 2016-01-19 2021-03-12 Pfizer Vacunas contra el cƔncer
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
EP3474890A1 (en) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Fƶrderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
JP7001687B2 (ja) 2016-08-05 2022-02-04 ć‚µćƒŽćƒ•ć‚£ ćƒ‘ć‚¹ćƒ„ćƒ¼ćƒ« ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ć‚£ćƒƒćƒ‰ 多侔č‚ŗē‚ŽēƒčŒå¤šē³–体ļ¼ć‚æćƒ³ćƒ‘ć‚Æč³Ŗć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆēµ„ęˆē‰©
JP7001686B2 (ja) 2016-08-05 2022-02-04 ć‚µćƒŽćƒ•ć‚£ ćƒ‘ć‚¹ćƒ„ćƒ¼ćƒ« ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ć‚£ćƒƒćƒ‰ 多侔č‚ŗē‚ŽēƒčŒå¤šē³–体ļ¼ć‚æćƒ³ćƒ‘ć‚Æč³Ŗć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆēµ„ęˆē‰©
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
KR102622188B1 (ko) 2016-10-07 2024-01-05 ģ—”ķ„°ė”¬ ģ—ģŠ¤.ģ—ģ“. ģ•” ģ¹˜ė£Œė„¼ ģœ„ķ•œ ė©“ģ—­ģ›ģ„± ķ™”ķ•©ė¬¼
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
AU2018208844B2 (en) 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN118021947A (zh) 2017-01-31 2024-05-14 č¾‰ē‘žå¤§čÆ厂 脑膜ē‚Žå„ˆē‘ŸčŒē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
CN110520154B (zh) * 2017-03-15 2023-08-04 ę Ŗ式会ē¤¾Lg化学 多价č‚ŗē‚Žé“¾ēƒčŒē–«č‹—ē»„合ē‰©
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3600391A1 (en) 2017-03-31 2020-02-05 GlaxoSmithKline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP7132954B2 (ja) 2017-06-10 2022-09-07 ć‚¤ćƒ³ćƒ™ćƒ³ćƒˆćƒ—ćƒ©ć‚¤ć‚ŗ ćƒŖ惟惆惃惉 ćƒ©ć‚¤ć‚¢ćƒ“ćƒŖćƒ†ć‚£ ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ ę”¹å–„ć•ć‚ŒćŸå…ē–«åŽŸę€§åŠć³ēµåˆę“»ę€§ć‚’ęä¾›ć™ć‚‹ļ¼’ä¾”又ćÆå¤šä¾”ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆå¤šē³–ć‚’å«ć‚€å¤šä¾”ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆćƒÆć‚Æćƒćƒ³
BR112020001768A2 (pt) 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. mĆ©todo de reforƧar uma resposta imune prĆ©-existente contra haemophilus influenzae e moraxella catarrhalis nĆ£o tipĆ”veis em um indivĆ­duo, e, protocolo de vacinaĆ§Ć£o.
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
EP3720483A2 (en) 2017-12-06 2020-10-14 Merck Sharp&Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7288451B2 (ja) 2018-02-05 2023-06-07 ć‚µćƒŽćƒ•ć‚£ ćƒ‘ć‚¹ćƒ„ćƒ¼ćƒ« ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ć‚£ćƒƒćƒ‰ 多侔č‚ŗē‚ŽēƒčŒå¤šē³–体ļ¼ć‚æćƒ³ćƒ‘ć‚Æč³Ŗč¤‡åˆä½“ēµ„ęˆē‰©
MX2020008198A (es) 2018-02-05 2020-09-22 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente neumococica.
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
CN112118863B (zh) 2018-04-11 2025-05-30 ꁩē‰¹ē½—姆公åø ē”ØäŗŽé¢„é˜²å’Œę²»ē–—ē™Œē—‡ēš„ęŠ—åŽŸč‚½
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
CA3096358A1 (en) 2018-04-18 2019-10-24 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharide and immunogenic conjugate thereof
BR112021000529A2 (pt) 2018-07-19 2021-04-06 Glaxosmithkline Biologicals S.A. Processos para preparar polissacarĆ­deos secos
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7585203B2 (ja) 2018-12-12 2024-11-18 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ 免ē–«åŽŸę€§å¤šé‡ćƒ˜ćƒ†ćƒ­ęŠ—原多ē³–ļ¼ć‚æćƒ³ćƒ‘ć‚Æč³Ŗć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆćŠć‚ˆć³ćć®ä½æē”Ø
JP7551618B2 (ja) 2018-12-12 2024-09-17 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ļ¼Æļ¼ēµåˆåž‹ć‚°ćƒŖć‚³ć‚·ćƒ«åŒ–ć®ćŸć‚ć®äæ®é£¾ć‚­ćƒ£ćƒŖć‚¢ć‚æćƒ³ćƒ‘ć‚Æč³Ŗ
KR102735230B1 (ko) 2018-12-19 2024-11-29 ėØøķ¬ ģƒ¤ķ”„ ģ•¤ė“œ ė” ģ—˜ģ—˜ģ”Ø ģŠ¤ķŠøė ™ķ† ģ½”ģæ ģŠ¤ ė‰“ėŖØė‹ˆģ•„ģ— ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œ-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ė„¼ ķ¬ķ•Øķ•˜ėŠ” ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ģ‚¬ģš© ė°©ė²•
JP7644454B2 (ja) * 2019-01-11 2025-03-12 ćƒŽćƒ¼ć‚¹ć‚¦ć‚§ć‚¹ć‚æćƒ³ ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ 原ę øē“°čƒžęŗ¶č§£ē‰©ć«ćŠć‘ć‚‹ćƒć‚¤ć‚Ŗć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆćƒÆć‚Æćƒćƒ³ć®åˆęˆ
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
US20220211859A1 (en) 2019-05-10 2022-07-07 Glaxosmithkline Biologicals Sa Conjugate production
WO2021023691A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2021023692A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
CN115605222A (zh) 2019-09-27 2023-01-13 č¾‰ē‘žå…¬åøļ¼ˆUsļ¼‰ 脑膜ē‚Žå„ˆē‘Ÿę°čŒē»„合ē‰©åŠå…¶ę–¹ę³•
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
BR112022009100A2 (pt) 2019-11-15 2022-07-26 Enterome S A PeptĆ­deos antigĆŖnicos para prevenĆ§Ć£o e tratamento de malignidade de cĆ©lulas b
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
US20220409539A1 (en) * 2019-12-30 2022-12-29 Fraunhofer Usa Inc. Particles for multi-dose delivery
KR20220144393A (ko) 2020-02-21 2022-10-26 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‹¹ė„˜ģ˜ ģ •ģ œ
PE20230170A1 (es) 2020-02-23 2023-02-01 Pfizer Composiciones de escherichia coli y sus metodos
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
JP7664386B2 (ja) 2020-10-27 2025-04-17 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ 大č…ø菌ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ę–¹ę³•
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202245836A (zh) 2021-02-19 2022-12-01 ē¾Žå•†č³½č«¾č²å·“ę–Æ德公åø 重ēµ„ļ½‚åž‹č…¦č†œē‚ŽēƒčŒē–«č‹—
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
TW202306969A (zh) 2021-05-28 2023-02-16 ē¾Žå•†č¼ē‘žå¤§č—„å»  包含ēµåˆä¹‹čŽ¢č†œé†£ęŠ—原ēš„免ē–«åŽŸēµ„合ē‰©åŠå…¶ē”Ø途
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
EP4463186A1 (en) 2022-01-13 2024-11-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
US20250205324A1 (en) 2022-03-31 2025-06-26 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
KR20250008122A (ko) 2022-05-11 2025-01-14 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė³“ģ”“ģ œė„¼ ź°–ėŠ” ė°±ģ‹  ģ œķ˜•ģ˜ ģ œģ”° ė°©ė²•
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
CN120404993A (zh) * 2025-07-03 2025-08-01 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
RU2121481C1 (ru) * 1988-12-16 1998-11-10 Š”Šµ Š”тŠ°Ń‚ Š”ŠµŃ€ ŠŠµŠ“ŠµŃ€Š»Š°Š½Š“ŠµŠ½ Š’ŠµŃ€Ń‚ŠµŠ³ŠµŠ½Š²Š¾Ń€Š“ŠøŠ³Š“ Š”Š¾Ń€ Š“Šµ ŠœŠøŠ½Šøстр Š’Š°Š½ Š’ŠµŠ»Š·ŠµŠ¹Š½, Š’Š¾Š»ŠŗсŠ³ŠµŠ·Š¾Š½Š“хŠµŠ¹Š“ эŠ½ ŠšŃŽŠ»Ń‚ŃŽŃ€ ŠœŠ¾Š“ŠøфŠøцŠøрŠ¾Š²Š°Š½Š½Ń‹Š¹ ŠæŠ½ŠµŠ²Š¼Š¾Š»ŠøŠ·ŠøŠ½, рŠµŠŗŠ¾Š¼Š±ŠøŠ½Š°Š½Ń‚Š½Š°Ń ŠæŠ»Š°Š·Š¼ŠøŠ“Š°, сŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя Š¼Š¾Š“ŠøфŠøцŠøрŠ¾Š²Š°Š½Š½Š¾Š³Š¾ ŠæŠ½ŠµŠ²Š¼Š¾Š»ŠøŠ·ŠøŠ½Š°, Š²Š°ŠŗцŠøŠ½Š°
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
WO1994000153A1 (en) 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
DK0618813T3 (da) * 1992-09-16 2002-03-11 Univ Tennessee Res Corp Antigen for M-hybridprotein og bƦrer for gruppe A streptococcal vaccine
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
JP3429313B2 (ja) 1993-05-18 2003-07-22 ć‚Ŗ惏悤ć‚Ŗćƒ»ć‚¹ćƒ†ć‚¤ćƒˆćƒ»ćƒŖć‚µćƒ¼ćƒćƒ»ćƒ•ć‚”ć‚¦ćƒ³ćƒ‡ćƒ¼ć‚·ćƒ§ćƒ³ äø­č€³ē‚ŽćƒÆć‚Æćƒćƒ³
CA2171942C (en) 1993-09-22 2010-12-14 Andrew Lees Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
KR19990007858A (ko) * 1995-04-17 1999-01-25 ģ”“ ė”ėø”ģœ .ė”œģš° ė°•ķ…Œė¦¬ģ•„ģ˜ ė¦¬ķ¬ķ”„ė”œķ…Œģøģœ¼ė”œ ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œģ— ėŒ€ķ•œ ė©“ģ—­ė°˜ģ‘ģ˜ ģœ ė„ė° ź°•ķ™”
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
CZ394297A3 (cs) 1995-06-07 1998-04-15 Biochem Vaccines Inc. StreptokokovĆ© proteiny teplotnĆ­ho Å”oku ze skupiny HSP70
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein eļæ½leniļæ½i iļæ½eren aļæ½ļæ½.
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
AU732520B2 (en) 1996-05-01 2001-04-26 Rockefeller University, The Choline binding proteins for anti-pneumococcal vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
AU739129B2 (en) 1997-06-03 2001-10-04 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
WO1999051266A2 (en) 1998-04-07 1999-10-14 Medimmune, Inc. Derivatives of pneumococcal choline binding proteins for vaccines
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
EP1109576B1 (en) 1998-08-19 2009-10-21 Baxter Healthcare SA Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
ATE422899T1 (de) * 1998-12-21 2009-03-15 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente fĆ¼r impstoffe
PT1163000E (pt) 1999-03-19 2008-03-20 Glaxosmithkline Biolog Sa Vacina contra antigƩnios de bactƩrias
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
ES2300255T3 (es) 2008-06-16
NO20014325L (no) 2001-11-14
IL145044A0 (en) 2002-06-30
CZ301445B6 (cs) 2010-03-03
CZ20013379A3 (cs) 2002-03-13
NO330736B1 (no) 2011-06-27
AR022965A1 (es) 2002-09-04
MY125202A (en) 2006-07-31
WO2000056359A3 (en) 2001-02-01
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
HK1043728A1 (en) 2002-09-27
US20030147922A1 (en) 2003-08-07
DE60032120D1 (de) 2007-01-11
SI1163000T1 (sl) 2008-06-30
AR022964A1 (es) 2002-09-04
US8926985B2 (en) 2015-01-06
JP5551579B2 (ja) 2014-07-16
KR100798212B1 (ko) 2008-01-24
DE60038166T2 (de) 2009-03-12
LU91652I9 (instruction) 2019-01-03
BRPI0009163B1 (pt) 2019-04-09
IL145045A0 (en) 2002-06-30
JP4846906B2 (ja) 2011-12-28
PL355180A1 (en) 2004-04-05
CY1107561T1 (el) 2013-03-13
KR20020000549A (ko) 2002-01-05
EP1776962A1 (en) 2007-04-25
NO20014322L (no) 2001-11-14
FR10C0008I1 (fr) 2010-03-26
PL204890B1 (pl) 2010-02-26
AU750913B2 (en) 2002-08-01
WO2000056358A3 (en) 2001-01-04
PL203917B1 (pl) 2009-11-30
LU91652I2 (fr) 2010-10-13
CN1351501A (zh) 2002-05-29
CY2009014I2 (el) 2010-07-28
EP1163000B1 (en) 2008-02-27
NL300415I1 (nl) 2009-12-01
CZ20013378A3 (cs) 2002-03-13
DK1163000T3 (da) 2008-04-28
TWI281403B (en) 2007-05-21
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
NO330532B1 (no) 2011-05-09
IL145043A0 (en) 2002-06-30
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
AU750788B2 (en) 2002-07-25
US9168313B2 (en) 2015-10-27
BR0009163A (pt) 2001-12-26
AU3430700A (en) 2000-10-09
AR022963A1 (es) 2002-09-04
AU3813600A (en) 2000-10-09
BRPI0009163B8 (pt) 2021-05-25
EP1880735A2 (en) 2008-01-23
HUS1500040I1 (hu) 2018-05-28
DE60038166D1 (de) 2008-04-10
PL355264A1 (en) 2004-04-05
KR20020000785A (ko) 2002-01-05
ATE387214T1 (de) 2008-03-15
CN1192798C (zh) 2005-03-16
CA2366314C (en) 2012-01-10
BE1025464I2 (instruction) 2019-03-06
NZ513840A (en) 2004-02-27
NO20014322D0 (no) 2001-09-05
DE60043930D1 (de) 2010-04-15
TWI286938B (en) 2007-09-21
WO2000056358A2 (en) 2000-09-28
US20100119544A1 (en) 2010-05-13
HK1043731A1 (en) 2002-09-27
CN1191852C (zh) 2005-03-09
HUP0200373A2 (en) 2002-06-29
EP1162999A2 (en) 2001-12-19
EP1162998A2 (en) 2001-12-19
FR10C0008I2 (fr) 2012-10-26
ATE459373T1 (de) 2010-03-15
KR20020001785A (ko) 2002-01-09
HU229968B1 (hu) 2015-03-30
WO2000056360A3 (en) 2001-01-25
AU750762B2 (en) 2002-07-25
CA2365296A1 (en) 2000-09-28
EP1880735A3 (en) 2008-03-12
PL355178A1 (en) 2004-04-05
DK1162999T3 (da) 2007-03-26
HUP0200664A2 (en) 2002-06-29
NZ513842A (en) 2004-05-28
EP2277535A2 (en) 2011-01-26
IL145044A (en) 2007-03-08
SI1162999T1 (sl) 2007-04-30
IL145043A (en) 2007-06-17
CN1391481A (zh) 2003-01-15
HK1043730A1 (zh) 2002-09-27
DE122009000054I1 (de) 2009-12-31
HK1043728B (en) 2007-06-22
US20060002961A1 (en) 2006-01-05
MXPA01009452A (es) 2002-08-06
CY2009014I1 (el) 2010-07-28
TR200102735T2 (tr) 2002-04-22
DE60032120T2 (de) 2007-09-20
EP1163000A2 (en) 2001-12-19
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
AU3291900A (en) 2000-10-09
ATE346608T1 (de) 2006-12-15
TR200102739T2 (tr) 2001-12-21
US20110217329A1 (en) 2011-09-08
JP2002540074A (ja) 2002-11-26
ES2339737T3 (es) 2010-05-25
TWI235064B (en) 2005-07-01
US20050031646A1 (en) 2005-02-10
MY125387A (en) 2006-07-31
HK1043731B (en) 2009-01-23
NZ513841A (en) 2001-09-28
PT1162999E (pt) 2007-02-28
TR200102736T2 (tr) 2002-04-22
CY1107390T1 (el) 2010-07-28
HUP0200367A2 (en) 2002-05-29
JP2002539273A (ja) 2002-11-19
HU228499B1 (en) 2013-03-28
EP2277535A3 (en) 2011-03-09
JP2002540075A (ja) 2002-11-26
NO20014323D0 (no) 2001-09-05
BR0009154A (pt) 2001-12-26
JP2011057713A (ja) 2011-03-24
WO2000056359A2 (en) 2000-09-28
BR0009166A (pt) 2001-12-26
CZ303653B6 (cs) 2013-01-30
KR100642044B1 (ko) 2006-11-10
CN1351503A (zh) 2002-05-29
CA2366314A1 (en) 2000-09-28
WO2000056360A2 (en) 2000-09-28
EP1162998B1 (en) 2010-03-03
NO2011014I2 (no) 2011-08-30
US20060093626A1 (en) 2006-05-04
NO20014325D0 (no) 2001-09-05
EP1162999B1 (en) 2006-11-29
NO2011014I1 (no) 2011-09-19

Similar Documents

Publication Publication Date Title
BE2018C020I2 (instruction)
LU91652I9 (instruction)
JP2002514480A5 (instruction)
BRPI0017527B8 (instruction)
IN2001KO01233A (instruction)
JP2002521141A5 (instruction)
BRPI0001672A2 (instruction)
JP2002521591A5 (instruction)
JP2002517184A5 (instruction)
JP2002519925A5 (instruction)
JP2002513244A5 (instruction)
JP2002506962A5 (instruction)
BRPI0001542A2 (instruction)
JP2002521163A5 (instruction)
JP2002513606A5 (instruction)
JP2002502016A5 (instruction)
BRPI0012675B8 (instruction)
JP2002522346A5 (instruction)
BRPI0017522A2 (instruction)
JP2002533952A5 (instruction)
HU0004772D0 (instruction)
BRMU7902607U2 (instruction)
FI4323U1 (instruction)
JP2001182743A5 (instruction)
BRPI9917761A2 (instruction)